{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:01:51Z","timestamp":1791594111715,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T00:00:00Z","timestamp":1612224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Endocrino Diabet &amp; Metabol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>In addition to its role in the pathogenesis of migraine, calcitonin gene\u2010related peptide (CGRP) is implicated in the regulation of insulin secretion. However, there are limited data on the use of CGRP inhibitor monoclonal antibodies in individuals who are overweight\/obese and those with diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Two randomized, double\u2010blind, placebo\u2010controlled trials were conducted to assess the safety and metabolic effects of eptinezumab in non\u2010migraine overweight\/obese patients (study 1) and patients with type 1 diabetes (T1D; study 2). The primary end\u2010point in overweight\/obese patients was safety and changes in basal metabolic rate (BMR), defined as the energy expenditure during the fasting and resting states. In patients with T1D, the primary end\u2010points were safety and insulin sensitivity as assessed by the bodyweight and insulin concentration corrected glucose infusion rate (M\/I).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 24 patients were enrolled in study 1, and 21 patients were enrolled in study 2. In overweight\/obese patients, there was no significant difference in the least squares (LS) mean change in BMR between the eptinezumab\u2010 and placebo\u2010treated patients from baseline to day 7 (6.4 vs \u221225.2\u00a0Kcal\/day; LS mean difference 31.6 [95% confidence interval \u221290.6, 153.8]). In patients with T1D, there was no significant difference in insulin sensitivity between the eptinezumab and placebo groups. Eptinezumab was well tolerated in both studies with a similar rate of adverse events between treatment groups, and no new safety signals were identified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Eptinezumab was well tolerated and not associated with adverse metabolic effects in patients who were overweight\/obese or had T1D, providing ongoing support for the use of eptinezumab in these subgroups of patients with migraine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/edm2.217","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T05:01:23Z","timestamp":1612587683000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2733-6386","authenticated-orcid":false,"given":"Brian","family":"Baker","sequence":"first","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schaeffler","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Hirman","sequence":"additional","affiliation":[{"name":"Pacific Northwest Statistical Consulting Woodinville WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hompesch","sequence":"additional","affiliation":[{"name":"ProSciento, Inc. Chula Vista CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pederson","sequence":"additional","affiliation":[{"name":"Lundbeck Seattle BioPharmaceuticals, Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Smith","sequence":"additional","affiliation":[{"name":"Alder BioPharmaceuticals, Inc. (now known as Lundbeck Seattle BioPharmaceuticals, Inc.) Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0979-y"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13081"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.2002.00310.x"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/15360288.2019.1690616"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0284"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02046"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2006.05261.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2005.00928.x"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnz055"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2012.00161"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000262045.11646.b1"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2010.00791.x"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318212ab1e"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d0cc8b"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.06.005"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313458"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-013-0411-y"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1341441"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.26008"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020468902694"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9367-0"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13407"}],"container-title":["Endocrinology, Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.217","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/edm2.217","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/edm2.217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:50:15Z","timestamp":1693216215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/edm2.217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1002\/edm2.217"],"URL":"https:\/\/doi.org\/10.1002\/edm2.217","archive":["Portico"],"relation":{},"ISSN":["2398-9238","2398-9238"],"issn-type":[{"value":"2398-9238","type":"print"},{"value":"2398-9238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,2]]},"assertion":[{"value":"2020-08-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00217"}}